Accelerated approval of anti-Ai New Drugs independently researched and developed in China
December 02, 2016 Source: Beijing Youth Daily
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];This medicine can change the daily medication used by patients to the current weekly injection. The main person in charge of clinical trials, Professor Wu Wei, director of the Beijing You'an Hospital Infection Center, introduced the first anti-Ai Xin drug aimed at effectively treating Chinese patients. The main treatment for AIDS is oral administration. The patient needs to take the medicine for life. The toxic side effects of the medicine will cause liver and kidney damage to the patient, and drug resistance will occur after a period of time. The new drug developed this time adopts the method of injection and administration, and has two distinct characteristics: one is once a week, and the other is effective against a drug-resistant virus. In terms of effectiveness and safety, it is better than the second-line drugs commonly used in developed countries, with less toxic side effects, especially the damage to the kidneys, and the patient's daily medication is changed to a weekly injection. The result is a major breakthrough in the field of anti-AIDS drug research and development in the world.
According to reports, the research team of Beijing You'an Hospital divided 208 cases of HIV-infected patients with first-line drug treatment into two groups for multi-center randomized clinical trials for 48 weeks. The interim data summary showed that 80.4% of the patients in the experimental group were suppressed to lower than the detection sensitivity, while only 66.0% of the non-test group achieved this primary efficacy goal. Recently, the Expert Group of the Food and Drug Inspection and Inspection Center of the State Food and Drug Administration came to Beijing You'an Hospital to conduct a review of Phase III drug clinical trial data on Aibo Weitai, a new generation of anti-AIDS drug independently developed by China. The self-developed anti-AIDS drugs entered the final sprint stage before the market and are expected to become the world's first long-acting anti-AIDS drug.
Dingmin Pharmaceutical supply Decitabine API and Decitabine Intermediates with high purity and best price. The main products CAS No are as follows: 3601-89-6, 2353-33-5, 931-86-2, 3601-90-9. Sample can be sent if you request.
Welcome to do business with us. Please email to us directly.
Cas 2353-33-5,Decitabine Intermediates,5-Azacytosine
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com